Skip To Main Content
Sateesh Kumar Vemula on Muck Rack

Sateesh Kumar Vemula

As seen in: MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sateesh Kumar

Contact Sateesh Kumar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Quality by Design (QbD) Approach to Develop Colon-Specific Ketoprofen Hot-Melt Extruded Pellets: Impact of Eudragit® S 100 Coating on the In Vitro Drug Release

|
By Sateesh Kumar Vemula, Sagar Narala, Prateek Uttreja, Nagarjuna Narala
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Pharmaceutics | Free Full-Text | Continuous Manufacturing of Solvent-Free Cyclodextrin Inclusion Complexes for Enhanced Drug Solubility via Hot-Melt Extrusion: A Quality by Design Approach

|
By Siva Ram Munnangi, Nagarjuna Narala, Preethi Lakkala, Sateesh Kumar Vemula
| MDPI
1. Introduction Integrating high-throughput screening in drug discovery led to the emergence of lipophilic compounds. However, formulation scientists need help dealing with limited solubility during development and manufacturing. Over 40% of APIs in the market and 70% in the developmental pipeline exhibit poor solubility [1]. Poor solubility may decrease active pharmaceutical ingredients (APIs)’ bioavailability and require higher doses [2].
Open in Who Shared Issue with article?
See all 2 articles